• Product &
    Technologies
    • Organism-on-Chip technology
    • SydLab™ One Platform
    • Consumables & Reagents
    • SydLab™ Analyzer Software Modules
    • SydLab™ One Discovery Pack
  • Contract
    Laboratory Solutions
    • Aging and Longevity Studies
    • Neurodegenerative Studies
    • Toxicity Studies
    • Compound Efficacy Studies
    • Microbiome Studies
    • Custom Studies
  • Applications
    • Fundamental Research
      • Aging and age-related Diseases
      • Neurodegenerative Diseases
    • Candidate Discovery
      • Aging and age-related Diseases
      • Neurodegenerative Diseases
    • Safety Toxicology
      • Developmental and Reproductive Toxicity
  • Industries
    • Biopharma and Biotech
    • Academic Research
    • Agro-science
    • Nutrition and Nutraceuticals
    • Cosmetics
  • About Nagi
    • Our story
    • News
    • Events
    • Careers
  • Resources
    • Resource Center
    • Nagi Blog
  • Contact us
SydLab™ Users Hub
  • LinkedIn
  • X
  • Nagi Bioscience was awarded an Innosuisse Innovation Project in 2020

    Nagi Bioscience was awarded an Innosuisse Innovation Project in 2020

    Nagi Bioscience was awarded an Innosuisse Innovation Project in 2020.

    March 1, 2021
  • Nagi Bioscience was named as a TOP 100 Swiss startups and TOP 10 newcomers of 2020

    Nagi Bioscience was named as a TOP 100 Swiss startups and TOP 10 newcomers of 2020

    Nagi Bioscience was named as a TOP 100 Swiss startups and TOP 10 newcomers of 2020. And we did it again this year 2022! We have been nominated for TOP 100 Swiss…

    September 9, 2020
  • Nagi Bioscience listed in Bilan’s TOP 50 Swiss start-up companies 2020!

    Nagi Bioscience listed in Bilan’s TOP 50 Swiss start-up companies 2020!

    Nagi Bioscience was selected by the prestigious Swiss economic newspaper Bilan among the Top 50 startups in which to invest in 2020.

    March 11, 2020
  • Nagi Bioscience is proud to announce the closing of a CHF 1.8M seed financing round

    Nagi Bioscience is proud to announce the closing of a CHF 1.8M seed financing round

    Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals.

    December 20, 2019
  • Nagi Bioscience was attending the Demo Day at La Forge

    Nagi Bioscience was attending the Demo Day at La Forge

    Today, our CEO Matteo Cornaglia was on stage for pitching the company at the LaForge Startup Demo Day on EPFL campus. Good vibes and interesting connections with the attendees. Thank you La Forge…

    May 23, 2019
  • A research grant funded by the Novartis Foundation

    A research grant funded by the Novartis Foundation

    We are glad to announce that our application was accepted by the Novartis Foundation for Medical-Biological Research. This research project will be coordinated in collaboration with the Laboratory of Microsystems at EPFL headed by the Prof….

    April 9, 2019
  • Nagi Bioscience won the Venture Kick final!

    Nagi Bioscience won the Venture Kick final!

    Nagi Bioscience wins the final phase of Venture Kick (130’000 CHF). The Venture Kick program has been an excellent support in terms of network, visibility and advices received from the coach and jury. Thank…

    January 31, 2019
  • Our startup is finalist of the competition “Inventer Demain”

    Our startup is finalist of the competition “Inventer Demain”

    Nagi Bioscience is among the 20 finalists of the competition “Inventer Demain” organized by the RTS, France 3TV and Bilan magazine. Ten Swiss start-ups and ten other French companies are competing this year. This…

    November 27, 2018
  • Nagi Bioscience won the Philip Morris Award Startup Competition!

    Nagi Bioscience won the Philip Morris Award Startup Competition!

    We are proud to be the winner  (CHF 10’000 cash prize) of the startup competition organized by Philip Morris Equity Partner! This competition, organized in the framework of MassChallenge Switzerland, aimed to support innovative…

    October 12, 2018
  • Nagi Bioscience successfully passed Venture Kick Stage 2

    Nagi Bioscience successfully passed Venture Kick Stage 2

    Nagi Bioscience passed stage 2 of Venture Kick! Let’s continue on our way: stage 3, here we come!

    June 29, 2018
←Previous Page
1 … 6 7 8 9 10 11
Next Page→
    • LinkedIn
    • X

Contact

Nagi Bioscience SA
EPFL Innovation Park (M)
Rue des Jordils 1A
1025 Saint-Sulpice, Switzerland
Email: info@nagibio.ch

Links

  • Contract Laboratories Solutions
  • Applications
  • Industries
  • Resources
  • About Nagi
  • Contact Us

Legal

  • Change Cookie Settings
  • Terms and Conditions
  • Privacy Policy

© 2025 Nagi Bioscience • All rights reserved